Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

June 28, 2024

Conditions
Platinum-resistant Ovarian Cancer
Interventions
DRUG

Paclitaxel

Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.

DRUG

Afuresertib

"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"

Trial Locations (47)

10467

Montefiore Medical Center, The Bronx

19090

Abington Memorial Hospital, Willow Grove

19107

Thomas Jefferson University, Philadelphia

23502

Virginia Oncology Associates, Norfolk

45219

University of Cincinnati Medical Center, Cincinnati

45242

OHCare Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati

60637

University of Chicago, Chicago

68114

Nebraska Methodist Hospital, Omaha

70433

Women's Cancer Care, Covington

72758

Highlands Oncology Group, Rogers

75601

USO Texas Oncology, Longview

76104

Texas Oncology, Fort Worth

76508

Baylor Scott & White Medical Center, Temple

77030

Houston Methodist Hospital, Houston

University of Texas Health Science Center at Houston, Houston

77380

Texas Oncology, The Woodlands

78240

US Texas Oncology, San Antonio

78731

Texas Oncology, Austin

80120

Rocky Mountain Cancer Centers, Littleton

85016

Arizona Oncology Associates, Phoenix

85711

Arizona Oncology, Tucson

87106

Southwest Women's Oncology Group, Albuquerque

92663

Gynecology Oncology Associates Newport Beach, Newport Beach

96826

Kapiolani Medical Center for Women and Children, Honolulu

98109

University of Washington/Seattle Cancer Care Alliance, Seattle

02111

Tufts Medical Center, Boston

01605

University of Massachusetts, Worcester

08103

MD Anderson Cancer Center at Cooper, Camden

07666

Holy Name Medical Center, Teaneck

02905

Women & Infants Hospital of Rhode Island, Providence

Unknown

Beijing Obstetrics & Gynecology Hospital, Capital Medical University, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Peking University Cancer Hospital, Beijing

Chongqing University Cancer Hospital, Chongqing

Sun Yat-sen University Cancer Center, Guangdong

Harbin Medical University Cancer Hospital, Heilongjiang

Henan Cancer Hospital, Henan

Hubei Cancer Hospital, Hubei

Hunan Cancer Hospital, Hunan

Jilin Cancer Hospital, Jilin

Liaoning Cancer Hospital, Liaoyang

Qilu Hospital of Shandong University, Shandong

Obstetrics & Gynecology Hospital of Fudan University, Shanghai

Zhongshan Hospital affiliated to Fudan University, Shanghai

West China Second University Hospital,Sichuan University, Sichuan

The Second Hospital of Tianjin Medical University, Tianjin

Women's Hospital school of medicine Zhejiang University, Zhejiang

All Listed Sponsors
lead

Laekna Limited

INDUSTRY

NCT04374630 - Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian | Biotech Hunter | Biotech Hunter